JP2022518392A5 - - Google Patents

Info

Publication number
JP2022518392A5
JP2022518392A5 JP2021540103A JP2021540103A JP2022518392A5 JP 2022518392 A5 JP2022518392 A5 JP 2022518392A5 JP 2021540103 A JP2021540103 A JP 2021540103A JP 2021540103 A JP2021540103 A JP 2021540103A JP 2022518392 A5 JP2022518392 A5 JP 2022518392A5
Authority
JP
Japan
Prior art keywords
seq
nos
vhh
molecule
vhh molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021540103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518392A (ja
JP7599425B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/050318 external-priority patent/WO2020144233A1/en
Publication of JP2022518392A publication Critical patent/JP2022518392A/ja
Publication of JP2022518392A5 publication Critical patent/JP2022518392A5/ja
Application granted granted Critical
Publication of JP7599425B2 publication Critical patent/JP7599425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021540103A 2019-01-09 2020-01-08 トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用 Active JP7599425B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305031 2019-01-09
EP19305031.7 2019-01-09
PCT/EP2020/050318 WO2020144233A1 (en) 2019-01-09 2020-01-08 Transferrin receptor-binding molecules, conjugates thereof and their uses

Publications (3)

Publication Number Publication Date
JP2022518392A JP2022518392A (ja) 2022-03-15
JP2022518392A5 true JP2022518392A5 (cg-RX-API-DMAC7.html) 2022-12-19
JP7599425B2 JP7599425B2 (ja) 2024-12-13

Family

ID=65236972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540103A Active JP7599425B2 (ja) 2019-01-09 2020-01-08 トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用

Country Status (9)

Country Link
US (1) US12152317B2 (cg-RX-API-DMAC7.html)
EP (1) EP3908608A1 (cg-RX-API-DMAC7.html)
JP (1) JP7599425B2 (cg-RX-API-DMAC7.html)
CN (1) CN113474369B (cg-RX-API-DMAC7.html)
AU (1) AU2020206593B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021013559A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124790A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191893A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020144233A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
JP7652807B2 (ja) * 2020-06-24 2025-03-27 サプリーム テクノロジーズ,ベー.フェー. 単一ドメイン抗体、サポニン及びエフェクター分子のコンジュゲート、それを含む医薬組成物、前記医薬組成物の治療的使用
CA3202539A1 (en) * 2020-12-02 2022-06-09 University Health Network Methods and uses for ndfip1 fusion polypeptides in treating neurodegenerative diseases, brain and/or traumatic and non-traumatic spinal cord injuries, and/or optic neuropathies
MX2023015520A (es) * 2021-07-01 2024-01-22 Denali Therapeutics Inc Conjugados de oligonucleotidos dirigidos al receptor de transferrina.
TW202330591A (zh) * 2021-11-19 2023-08-01 日商Jcr製藥股份有限公司 人類運鐵蛋白受體親和性肽
JP7889887B2 (ja) * 2021-12-02 2026-07-14 リンノ ファーマシューティカルズ インコーポレイテッド トランスフェリン結合抗体及びその使用
US11939391B2 (en) * 2021-12-06 2024-03-26 MedAbome, Inc. Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment
US20250066449A1 (en) * 2021-12-31 2025-02-27 Imnewrun, Inc. Blood-brain barrier permeable fusion protein and uses thereof
EP4504950A1 (en) 2022-04-01 2025-02-12 Takeda Pharmaceutical Company Limited Gene therapy for diseases with cns manifestations
CN119213030A (zh) * 2022-05-16 2024-12-27 戴纳立制药公司 转铁蛋白受体结合结构域和包含其的蛋白
CN120659627A (zh) * 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
US20260116990A1 (en) 2022-11-23 2026-04-30 Key2Brain Ab Vhh antibodies and uses thereof
EP4622668A1 (en) 2022-11-23 2025-10-01 Key2Brain AB Vhh antibodies and uses thereof
KR20250114322A (ko) * 2022-12-02 2025-07-29 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-tfr1 항체 및 이의 용도
TW202436352A (zh) * 2023-02-07 2024-09-16 日商Jcr製藥股份有限公司 人類運鐵蛋白受體親和性肽
CN116179607A (zh) * 2023-03-27 2023-05-30 迦进生物医药(上海)有限公司 一种human TfR2高表达的稳转细胞株及其构建方法和应用
CN116121306A (zh) * 2023-03-27 2023-05-16 迦进生物医药(上海)有限公司 一种human TfR1高表达的稳转细胞株及其构建方法和应用
JP2026519919A (ja) 2023-04-03 2026-06-19 ブイアイビー ブイゼットダブリュ 血液脳関門通過抗体
EP4480965A1 (en) 2023-06-22 2024-12-25 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
CN121969643A (zh) 2023-06-22 2026-05-01 维克塔-霍洛斯公司 转铁蛋白受体结合分子、其偶联物及其用于预防或治疗神经系统疾病的用途
EP4480964A1 (en) 2023-06-22 2024-12-25 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases
WO2024261332A2 (en) 2023-06-22 2024-12-26 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases
CN121773136A (zh) * 2023-07-04 2026-03-31 北京星奇原生物科技有限公司 抗-TfR1抗体及其用途
AU2024329222A1 (en) 2023-08-18 2026-02-12 Eli Lilly And Company Engineered transferrin receptor binding peptides as well as methods of making and using the same
US20250064958A1 (en) * 2023-08-22 2025-02-27 Eli Lilly And Company AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS
WO2025194170A1 (en) * 2024-03-15 2025-09-18 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of immune-related membrane proteins
WO2025194171A1 (en) * 2024-03-15 2025-09-18 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of g protein-coupled receptors
WO2025207959A1 (en) * 2024-03-27 2025-10-02 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
TW202602933A (zh) * 2024-03-28 2026-01-16 美商健臻公司 與轉鐵蛋白受體1的特異性表位結合的多肽
WO2025226642A1 (en) 2024-04-25 2025-10-30 Eli Lilly And Company Lipid nano delivery particles for targeted transport of nucleic acids and methods of making and using the same
WO2026142988A1 (en) * 2024-12-24 2026-07-02 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization of c-c chemokine receptor 6

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
EP2008666A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
AU2008322523B2 (en) 2007-11-16 2013-10-10 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN103443125B (zh) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
WO2014089209A2 (en) 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
DK2951201T3 (en) * 2013-01-30 2018-01-08 Vib Vzw Novel chimeric polypeptides for screening and drug detection purposes
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
EA035517B1 (ru) * 2014-03-06 2020-06-29 Нэшнл Рисеч Каунсил Оф Канада Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
CA2967830A1 (en) 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
CA3033082A1 (en) * 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Similar Documents

Publication Publication Date Title
JP7412521B2 (ja) Cd47に対するヒト化及びキメラモノクローナル抗体
CN104105708B (zh) PDGF受体β结合多肽
EP2501721B1 (en) Multivalent antibodies comprising fab-dsfv
AU2016304764C1 (en) Antigen binding constructs to target molecules
EP2523972B1 (en) Threevalent antibodies
CN106459216B (zh) 多特异性抗体构建体
EP2475682B1 (en) Multivalent antibodies
JP7360720B2 (ja) 抗pd―l1抗体およびその用途
US10472426B2 (en) Disulfide stabilized DVD-Ig molecules
JP2015509097A5 (cg-RX-API-DMAC7.html)
KR20150093744A (ko) Bcma 항원 결합 단백질
KR20240107202A (ko) 항-트랜스페린 수용체 항체 및 이의 용도
JP2022509372A5 (cg-RX-API-DMAC7.html)
WO2011061246A2 (en) Multivalent antibodies
WO2021207433A2 (en) Epitopes of sars-cov-2 neutralizing antibodies
KR20210071987A (ko) 항-cd79 항체 및 이들의 용도
JP2009529915A5 (cg-RX-API-DMAC7.html)
CN114652853A (zh) 抗il-4r抗体-药物偶联物及医药用途
WO2024022438A1 (zh) 一种抗rbd抗体及其用途
US11028132B1 (en) Half-life optimized linker composition
US12161889B2 (en) Blood brain barrier (BBB)-selective antibodies and methods of use thereof to target agents to the BBB
CN121263442A (zh) 抗il1rap抗体
WO2023071953A1 (zh) 抗cd26抗体及其应用
WO2022156670A1 (en) Multispecific antibodies against sars-cov-2 and methods of use thereof
TW202446418A (zh) 使用抗群落刺激因子1受體抗體治療慢性移植物抗宿主病相關閉塞性細支氣管炎症候群之方法